May 16th, 1:45 PM

Resident and Facility-level Correlations of Long-term Opioid Use in United States Nursing Homes

Jacob N. Hunnicutt
University of Massachusetts Medical School

Christine M. Ulbricht
University of Massachusetts Medical School

Anne Hume
University of Rhode Island

See next page for additional authors

Follow this and additional works at: https://escholarship.umassmed.edu/cts_retreat

Part of the Geriatrics Commons, Health Services Administration Commons, Pharmacy and Pharmaceutical Sciences Commons, and the Translational Medical Research Commons

Presenter Information
Jacob N. Hunnicutt, Christine M. Ulbricht, Anne Hume, and Kate L. Lapane

Keywords
nursing homes, opioid use, adverse drug effects

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.
RESIDENT AND FACILITY-LEVEL CORRELATIONS OF LONG-TERM OPIOID USE IN UNITED STATES NURSING HOMES

Jacob N. Hunnicutt, MPH; Christine Ulbricht, PhD; Anne Hume, PharmD; Kate Lapane, PhD
1University of Massachusetts Medical School; 2University of Rhode Island, Kingston, RI

Background: There is limited information on the prevalence and multilevel risk factors of long-term opioid use in older nursing home residents despite their high burden of pain and vulnerability to adverse drug events.

Objectives: To estimate the prevalence and correlates of long-term opioid use in United States (US) nursing homes.

Methods: We used comprehensive administrative/claims data (Minimum Data Set 3.0; Medicare Part D) from 2012 to conduct a cross-sectional study of 369,180 long-stay nursing home residents who were Medicare beneficiaries, ≥65 years old, and had no cancer. Resident factors of interest included demographics and physical/cognitive impairment, and facility factors included US census region and structural characteristics (eg, bed size, ownership). Long-term opioid use was defined as ≥90 cumulative days of opioid use during a 120 day observation window - defined using fill dates and days'. Modified Poisson models were used to estimate adjusted prevalence ratios (aPR) and 95% confidence intervals (CI) between resident/facility-level characteristics and long-term opioid use.

Results: Nearly one third of long-stay residents used any opioid, with 14.5% using opioids long-term. Among long-term users, 35.3% received a long-acting opioid, with 17.1% receiving high (≥90 mg/day oral morphine equivalents) daily doses. Hydrocodone (49.0%), tramadol (31.3%), and fentanyl (24.8%) were most commonly used. The prevalence of long-term use was higher in women (vs. men; aPR=1.20, 95% CI: 1.18-1.23) and those with no/mild cognitive impairment (vs. other; aPR=1.18, 95% CI: 1.16-1.20) or severe physical impairment (aPR=1.25; 95% CI: 1.22-1.27), and in government-owned nursing homes (vs. for-profit; aPR=1.10, 95% CI: 1.05-1.16). Long-term use varied by region (10.6% [Northeast] to 17.7% [Midwest]) and across facilities (median: 13.3% interquartile range: 6.7%-21.3%).

Conclusions: Long-term opioid use is substantially higher in nursing home residents than what has been previously reported in community-dwelling older adults. Further investigations of opioid safety in this frail population are needed.

Contact:
Jacob Hunnicutt, MPH
PhD Candidate, Clinical and Population Health Research
University of Massachusetts Medical School
Jacob.Hunnicutt@umassmed.edu